Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosedostat in Elderly/Refractory AML, MDS, or MM
NCT00689000Phase 2Completed
- Sponsor
- Chroma Therapeutics
- Start
- May 2006
- Primary completion
- Dec 2007
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tosedostat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM), sponsored by Chroma Therapeutics. Started May 2006; status: completed.
02
Drugs
tosedostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00689000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00689000.